Oruka Therapeutics, Inc. (HQ1)

Overview

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the advancement of novel monoclonal antibody treatments. With a focus on inflammatory and immunology (I&I) conditions, particularly psoriasis (PsO), the company is at the forefront of developing innovative therapies. Situated in Menlo Park, California, Oruka Therapeutics is on a mission to bring groundbreaking solutions to patients suffering from autoimmune and inflammatory diseases, leveraging cutting-edge scientific research to target and interrupt key pathways involved in these conditions.

Products and Services

ORKA-001: This lead product is a monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), a cytokine implicated in the pathogenesis of psoriasis (PsO). Currently in phase 1 clinical trials, ORKA-001 represents a pioneering approach to treating PsO by directly inhibiting one of the critical mediators of the disease's underlying inflammation.

ORKA-002: Another innovative product, ORKA-002, is designed to inhibit both interleukin-17A and interleukin-17F. These cytokines are central to the inflammatory process in psoriasis, psoriatic arthritis, and other inflammatory conditions. By targeting these critical components of the inflammatory pathway, ORKA-002 has the potential to offer a new therapeutic option for patients with these debilitating conditions.

ORKA-003: This product is in the early stages of development and targets an undisclosed pathway. Although specific details about ORKA-003 are not provided, its development underlines Oruka Therapeutics' commitment to expanding its portfolio of treatments for inflammatory and immunology indications by exploring novel targets and mechanisms.

ORKA-021: A unique approach within the company’s pipeline, ORKA-021 is a sequential combination regimen that utilizes both ORKA-002 and ORKA-001. This strategy aims to create a synergistic effect by targeting multiple pathways involved in the pathogenesis of psoriasis and potentially other inflammatory conditions as well. By combining these two agents, Oruka Therapeutics hopes to enhance efficacy and provide better outcomes for patients struggling with these chronic diseases.